SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jim Oravetz who wrote (234)3/26/2001 9:48:00 PM
From: Jim Oravetz  Read Replies (2) of 370
 
Replay of CC available till 3/30.

About 40 min or so long. Very positive outlook, IMHO. Not a negative on Vion that AZ did not want to continue their involvement. Kessman indicated that going forward with the rest of PI trials would not present significant $$ drain. Late in the CC he was asked about funding - good till mid-2002. He said that the science should prove that even in a difficult capital market, money will follow. He is looking for funding sources on an on going basis.

Levels of enzyme in cancer models were higher than if they put the enzyme directly into the cancer cells. AZ data was the same data sets that were prev. presented at the Lehman conf. PI trials must be completed to see that targets were really meet. They say high concentrations in cancer cells but none in non-cancer cells. However, even with the high concentrations, AZ did not like the degree of tumor shrinkage that they were expecting.

There was a comment on a new "tethered" form of delivering the prodrug. Idealy, they would like to have as many as 14 trials (PI) starting this year!

Other drugs in development, SHP and Triapine are also going well and there are higher expectations at Vion now than there were a year ago for these.

Jim
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext